Dr. Zhang on second-line treatment and beyond in refractory metastatic renal cell carcinoma
March 10th 2023“One of the key challenges in the refractory renal cell population is identifying mechanisms of resistance to immune checkpoint inhibitors, and really delving in and figuring out how to target those mechanisms of resistance,” says Zhang.
Dr. Shore on overall safety profile of darolutamide in prostate cancer patients
March 3rd 2023“What we saw in phase 3 studies and what we've seen in earlier studies—early phase 1/2 studies—is really a paucity of cognitive impairment and a paucity of depression with darolutamide that we've seen across the class of androgen receptor signaling inhibitors,” says Neal Shore, MD.
Developing personalized quality-of-life measures for patients undergoing radical cystectomy
March 2nd 2023“What we'd like to try to do in our research is see if we can begin to develop a tool that is more personalized for patients, that can provide a more useful approach to quality of life,” says Bernard H. Bochner, MD, FACS.
Dr. Maha Hussain highlights results of secondary analysis of ARASENS trial
February 28th 2023The secondary analysis Hussain presented at the GU Symposium showed that the risk of death was reduced by 32% across all volume and subgroups in men with mHSPC treated with the darolutamide-based triplet regimen.
Dr. Efstathiou on significance of genomic testing in prostate cancer
February 24th 2023“We need to pursue further education in the field and reach out to every community practice and make them understand that we do now have the guidelines in place, the reimbursement in place, and cost is going down for actually adding system-wide germline and somatic testing for these patients,” says Eleni Efstathiou, MD, PhD.